The next generation of brain tumor treatments.
At the Glasser Brain Tumor Center, we’re extremely proud to have a robust clinical trial research program that is advancing novel brain tumor treatments and offers patients hope. These clinical trials include:
- The “SURVIVE” Phase 2B trial of a first-of-its-kind brain cancer vaccine for patients with newly diagnosed glioblastoma
- A study of Berubicin – one of the first chemotherapy drugs to cross the blood-brain tumor barrier and overcome drug resistance – in adults with recurrent glioblastoma multiforme
- The ongoing development of novel treatments including immunotherapies, brain tumor vaccine strategies, oncolytic tumor viruses and other targeted therapies for high-grade primary brain tumors, low-grade gliomas, metastatic brain tumors and more.
If you’re interested in learning more about specific clinical trials that are underway and enrollment, please visit Atlantic Health System or call 908.522.5768.